Leerink Partners Initiates Coverage On NeuroPace with Outperform Rating, Announces Price Target of $22
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners analyst Mike Kratky has initiated coverage on NeuroPace (NASDAQ:NPCE) with an Outperform rating and set a price target of $22 for the company's stock.
January 30, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on NeuroPace with an Outperform rating and a price target of $22, which could positively influence the stock's performance in the short term.
Analyst coverage often impacts a stock's performance, especially when it is initiated with a positive rating. The Outperform rating and the price target of $22 suggest that Leerink Partners sees significant upside potential for NeuroPace, which could lead to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100